Pediatric Master Protocols - pharmacy.umaryland.edu · Hurdles - Pediatric Trials •No “healthy...
-
Upload
dangkhuong -
Category
Documents
-
view
218 -
download
0
Transcript of Pediatric Master Protocols - pharmacy.umaryland.edu · Hurdles - Pediatric Trials •No “healthy...
![Page 1: Pediatric Master Protocols - pharmacy.umaryland.edu · Hurdles - Pediatric Trials •No “healthy children volunteer” •Low rates of parental informed consent •Limited blood](https://reader031.fdocuments.in/reader031/viewer/2022031515/5cf97c8f88c99315288c5b01/html5/thumbnails/1.jpg)
Pediatric Master Protocols
Overall Assessment and Pathway Forward
Friday, September 23, 2016
![Page 2: Pediatric Master Protocols - pharmacy.umaryland.edu · Hurdles - Pediatric Trials •No “healthy children volunteer” •Low rates of parental informed consent •Limited blood](https://reader031.fdocuments.in/reader031/viewer/2022031515/5cf97c8f88c99315288c5b01/html5/thumbnails/2.jpg)
Mycamine®(micafungin sodium)
• Member of the echinocandin class of antifungals
• Approved in the U.S. for adults and pediatric patients > 4 months of age for:• Treatment of candidemia, acute disseminated candidiasis, Candida peritonitis, and abscesses;
• Treatment of esophageal candidiasis;
• Prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplant
2Confidential and priviledged
![Page 3: Pediatric Master Protocols - pharmacy.umaryland.edu · Hurdles - Pediatric Trials •No “healthy children volunteer” •Low rates of parental informed consent •Limited blood](https://reader031.fdocuments.in/reader031/viewer/2022031515/5cf97c8f88c99315288c5b01/html5/thumbnails/3.jpg)
Mycamine: Increased Weight-normalized Clearance in Infants < 4 Months of Age
Benjamin Clin Pharmacol Ther, 2010;87(1):93-9; Hope AAC, 20073
Confidential and priviledged
![Page 4: Pediatric Master Protocols - pharmacy.umaryland.edu · Hurdles - Pediatric Trials •No “healthy children volunteer” •Low rates of parental informed consent •Limited blood](https://reader031.fdocuments.in/reader031/viewer/2022031515/5cf97c8f88c99315288c5b01/html5/thumbnails/4.jpg)
Population PK Bridging Study Demonstrates Dose of 10 mg/kg is Most Appropriate
• Monte Carlo simulations demonstrated that a Mycamine dose of 10 mg/kg achieves the target exposure in >85% of the population with <10% of the population at risk of reaching the range where non-clinical toxicities were seen, notably liver enzyme changes
AUC > 580 mg*h/L
AUC > 170 mg*h/L
4Confidential and priviledged
![Page 5: Pediatric Master Protocols - pharmacy.umaryland.edu · Hurdles - Pediatric Trials •No “healthy children volunteer” •Low rates of parental informed consent •Limited blood](https://reader031.fdocuments.in/reader031/viewer/2022031515/5cf97c8f88c99315288c5b01/html5/thumbnails/5.jpg)
Further Investigation in Young Infants May Be Necessary
• Unique drug disposition compared to older children and adults
• Prominent CNS disease in this population• CNS involvement requires higher target exposures for treatment
• There was limited safety and efficacy of this dose and exposure
5Confidential and priviledged
![Page 6: Pediatric Master Protocols - pharmacy.umaryland.edu · Hurdles - Pediatric Trials •No “healthy children volunteer” •Low rates of parental informed consent •Limited blood](https://reader031.fdocuments.in/reader031/viewer/2022031515/5cf97c8f88c99315288c5b01/html5/thumbnails/6.jpg)
Phase 3 Study Overview
Phase 3, randomized (2:1), multi-center, double-blind, non-inferiority study comparing micafungin to conventional amphotericin B
Primary Endpoint: Fungal free survival - 1 week following the last dose of study drug
Population: 225 infants, 2-120 days of life with culture proven candidiasis
Randomization stratification: gestational age and region
6Confidential and priviledged
![Page 7: Pediatric Master Protocols - pharmacy.umaryland.edu · Hurdles - Pediatric Trials •No “healthy children volunteer” •Low rates of parental informed consent •Limited blood](https://reader031.fdocuments.in/reader031/viewer/2022031515/5cf97c8f88c99315288c5b01/html5/thumbnails/7.jpg)
Study Conduct: Getting Started
• Contacted pediatric clinical trial networks globally experienced with disease state, including:• Pediatric Trials Network, Pediatric Fungal Network, Pediatrix, Children’s Research Network
(UK), International Conference of Clinical Neonatology (ICCN), Treat Infections in Neonates (TINN) (EU)
• Established a Scientific Committee to advise on study• Daniel Benjamin, MD, PhD (Protocol Chair); Duke, North Carolina, USA
• William Hope, MD; University of Liverpool Liverpool, UK
• P. Brian Smith, MD; Duke, Durham, North Carolina, USA
• David Kaufman, MD; University of Virginia Charlottesville, Virginia, USA
• Thomas J. Walsh, MD; Weill Cornell Medical Center New York, New York, USA
• Antonio Arrieta, MD; Children’s Hospital of Orange County, Orange, California, USA
7Confidential and priviledged
![Page 8: Pediatric Master Protocols - pharmacy.umaryland.edu · Hurdles - Pediatric Trials •No “healthy children volunteer” •Low rates of parental informed consent •Limited blood](https://reader031.fdocuments.in/reader031/viewer/2022031515/5cf97c8f88c99315288c5b01/html5/thumbnails/8.jpg)
Site Selection Challenges
Approached 597 sites/70 countries
Selected 93
Initiated
71 sites/23
countries
8Confidential and priviledged
![Page 9: Pediatric Master Protocols - pharmacy.umaryland.edu · Hurdles - Pediatric Trials •No “healthy children volunteer” •Low rates of parental informed consent •Limited blood](https://reader031.fdocuments.in/reader031/viewer/2022031515/5cf97c8f88c99315288c5b01/html5/thumbnails/9.jpg)
Reasons for Not Participating
9Confidential and priviledged
![Page 10: Pediatric Master Protocols - pharmacy.umaryland.edu · Hurdles - Pediatric Trials •No “healthy children volunteer” •Low rates of parental informed consent •Limited blood](https://reader031.fdocuments.in/reader031/viewer/2022031515/5cf97c8f88c99315288c5b01/html5/thumbnails/10.jpg)
10
10Confidential and priviledged
![Page 11: Pediatric Master Protocols - pharmacy.umaryland.edu · Hurdles - Pediatric Trials •No “healthy children volunteer” •Low rates of parental informed consent •Limited blood](https://reader031.fdocuments.in/reader031/viewer/2022031515/5cf97c8f88c99315288c5b01/html5/thumbnails/11.jpg)
Enrollment Challenges
216 screened
31 randomized
30
treated
2 ye
ars and
5 m
on
ths
11Confidential and priviledged
![Page 12: Pediatric Master Protocols - pharmacy.umaryland.edu · Hurdles - Pediatric Trials •No “healthy children volunteer” •Low rates of parental informed consent •Limited blood](https://reader031.fdocuments.in/reader031/viewer/2022031515/5cf97c8f88c99315288c5b01/html5/thumbnails/12.jpg)
Pharmacokinetic Sampling
• Plasma PK • 17 participants (57%)
• CSF PK• 2 participants (7%)
12Confidential and priviledged
![Page 13: Pediatric Master Protocols - pharmacy.umaryland.edu · Hurdles - Pediatric Trials •No “healthy children volunteer” •Low rates of parental informed consent •Limited blood](https://reader031.fdocuments.in/reader031/viewer/2022031515/5cf97c8f88c99315288c5b01/html5/thumbnails/13.jpg)
Pediatric Trials NetworkTime to Site Activation
Site
Time From Selection to Activation (months)
Status
1 17 Selected
2 16 Selected
3 13 Active
4 13 Active
5 13 Selected
6 13 Selected
7 12 Selected
8 11 Active
9 10 Active
10 10 Active
11 8 Active
12 8 Active
13 7 Active
14 7 Active
15 6 Active16 5 Active17 5 Active18 4 Active19 4 Active
Average – 10 months
![Page 14: Pediatric Master Protocols - pharmacy.umaryland.edu · Hurdles - Pediatric Trials •No “healthy children volunteer” •Low rates of parental informed consent •Limited blood](https://reader031.fdocuments.in/reader031/viewer/2022031515/5cf97c8f88c99315288c5b01/html5/thumbnails/14.jpg)
Add-on PK Therapy Studies - InfantsDrug N Citation
Micafungin 12 PIDJ 2009
Micafungin 12 CPT 2010
Fluconazole loading dose 13 PIDJ 2011
Fluconazole ECMO 20 PIDJ 2012
Daptomycin 20 PIDJ 2012
Meropenem 200 PIDJ 2013
Acyclovir 32 PIDJ 2014
Metronidazole 24 AAC 2012
Anidulafungin 15 CPT 2011
Cefazolin 10 pending
Piperacillin-tazobactam 32 AAC 2014
![Page 15: Pediatric Master Protocols - pharmacy.umaryland.edu · Hurdles - Pediatric Trials •No “healthy children volunteer” •Low rates of parental informed consent •Limited blood](https://reader031.fdocuments.in/reader031/viewer/2022031515/5cf97c8f88c99315288c5b01/html5/thumbnails/15.jpg)
Hurdles - Pediatric Trials
• No “healthy children volunteer”
• Low rates of parental informed consent
• Limited blood volume
• Lack of clinical pharmacology expertise
• Timing of consent
• Contamination
• Sick population – increases variability
• Variability in site enrollment
• Clinician concerns/beliefs about therapies and trials
• Variability in site outcomes
• Competing research priorities
• Contracting
• IRBs
• Study documents - CRF, protocol, MOP, SAP, ICF
• Data management
• Site training
• Cost
• Limited number of patients with the disease
![Page 16: Pediatric Master Protocols - pharmacy.umaryland.edu · Hurdles - Pediatric Trials •No “healthy children volunteer” •Low rates of parental informed consent •Limited blood](https://reader031.fdocuments.in/reader031/viewer/2022031515/5cf97c8f88c99315288c5b01/html5/thumbnails/16.jpg)
Efficiencies in master protocols
![Page 17: Pediatric Master Protocols - pharmacy.umaryland.edu · Hurdles - Pediatric Trials •No “healthy children volunteer” •Low rates of parental informed consent •Limited blood](https://reader031.fdocuments.in/reader031/viewer/2022031515/5cf97c8f88c99315288c5b01/html5/thumbnails/17.jpg)
Conclusions
• It’s doable
• Pediatrics is perfect location
• NICHD’s Pediatric Trials Network has done this
• Industry should do it for PREA and exclusivity
• EMA/FDA should deleverage risk by putting some thoughts in writing when they provide comments to PIP or WR